Home›Trial›NCT06005493
🔬NCT06005493Phase 1Phase 2RECRUITING

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Study Summary

This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.

Conditions
Gastric CancerGastro-esophageal Junction CancerPancreatic Ductal AdenocarcinomaEsophageal Adenocarcinoma
Interventions / Drugs
AZD5863
View on ClinicalTrials.gov ↗
Sponsor
AZN
AstraZeneca
Oncology/Respiratory
F15/100
Study Details
Enrollment280 participants
Primary Completion—
Lead SponsorAstraZeneca
Data Retrieved2026-04-11 02:55:19.910082+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.